The primary therapeutic role of Aubagio is generally as a disease-modifying therapy (DMT) for conditions involving episodic or fluctuating manifestations, such as relapsing forms of Multiple Sclerosis (MS). It is a long-term treatment strategy used to help manage the underlying chronic autoimmune inflammation that is linked to disease activity. The medication is commonly used across conditions presenting with acute episodes, relevant in situations involving Clinically Isolated Syndrome, Relapsing-Remitting MS, and certain forms of Secondary Progressive MS. The therapeutic approach is applied in addressing conditions where functional stability becomes affected and supports patients during episodes of heightened discomfort. It is used to manage these relapsing forms of the condition.

This medication plays a role in managing symptoms related to recurrent, episodic changes that create noticeable physiological strain. It is relevant when symptoms become more disruptive during flare-ups. Its benefit is relevant for easing the overall symptom burden associated with long-term functional strain, which helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

---

Quick Fact: Support for Episodic Symptom Patterns

Property	Description
Primary Therapeutic Goal	Managing the recurrent, episodic nature of MS
Core Symptom Domain	Helps address symptom clusters associated with acute or episodic changes
Patient Benefit	Supports functional stability and helps ease the overall symptom burden

Regulatory References

1. FDA Label for Aubagio (Teriflunomide)

Who Can and Cannot Use Aubagio 14mg?

This medication is officially approved for use in adult patients with relapsing forms of the underlying condition. Eligibility is strictly defined by regulatory documents, which establish groups who must not use the medicine and those who require conditional use.

Contraindications (Must Not Use)

Use is contraindicated in several populations, including: pregnant women and females of reproductive potential not using effective contraception; breast-feeding women; patients with severe hepatic impairment (Child-Pugh Class C); patients with severe immunodeficiency states or significantly impaired bone marrow function; and patients with known hypersensitivity to teriflunomide or leflunomide.

Conditional and Restricted Eligibility

Category	Official Regulatory Status
Pediatric Use	Approved for use in patients aged 10 years and above; safety and efficacy are not established for children under 10.
Organ Function	Contraindicated in severe renal impairment undergoing dialysis. Allowed in mild to severe renal impairment not on dialysis, and in mild/moderate hepatic impairment.
Geriatric Use	Use in patients aged 65 years and over requires caution due to insufficient data.
Co-medication	Contraindicated for patients currently treated with leflunomide.

Interactions with other medicines and products

Aubagio 14mg (Teriflunomide) has a documented interaction profile that primarily involves its regulatory effects on drug-metabolizing enzymes and transporters.

Contraindicated Combinations and Key Restrictions

Classification	Interacting Substance	Official Constraint
Contraindicated	Leflunomide	Co-administration is formally prohibited due to the risk of excessive active drug exposure.
Not Recommended	Live Vaccines	Generally not recommended due to the potential for added infection risk related to immunosuppressive effects.

Pharmacokinetic and Pharmacodynamic Interactions

Teriflunomide is officially documented as an inhibitor of the CYP2C8 enzyme and the BCRP and OATP1B1/B3 transporters. This activity increases the exposure (plasma concentration) of co-administered medicines that are substrates of these systems (e.g., Rosuvastatin or Repaglinide). For Rosuvastatin, the dose is officially restricted to 10 mg once daily when co-administered.

Conversely, Teriflunomide is a weak inducer of the CYP1A2 enzyme, which results in a documented decrease in the exposure of its substrates (e.g., Theophylline and Duloxetine). The exposure of oral contraceptives (Ethinyl Estradiol and Levonorgestrel) is documented to increase. Additionally, co-administration with other potentially hepatotoxic or immunosuppressive therapies is subject to regulatory warning due to the risk of additive toxicity.

Other Documented Interactions

• Warfarin: Co-administration results in a documented decrease in the peak International Normalized Ratio (INR).
• Accelerated Elimination: Cholestyramine or activated charcoal are formally documented binding agents used to rapidly lower plasma concentrations when required by specific conditions.
• Alcohol: Consumption of substantial quantities of alcohol is associated with an increased risk of elevated liver enzymes.

Core Action: Selective Enzyme Inhibition of DHODH

The drug's primary biological target is the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH) . By selectively and reversibly inhibiting DHODH, the molecule effectively blocks the de novo pyrimidine synthesis pathway, which is essential for creating the nucleotides needed to build DNA and RNA. This molecular block influences a cascade that affects the rate of lymphocyte production.

---

Cytostatic Effect on Activated Lymphocytes

This enzyme blockade preferentially imposes metabolic stress on activated T and B lymphocytes, which rely heavily on the de novo pathway for their high proliferative rate. The resulting shortage of nucleotides causes these cells to halt their division cycle (cytostatic effect). Since resting lymphocytes utilize the pyrimidine salvage pathway, which is unaffected, the mechanism limits the expansion of the proliferating lymphocyte pool while maintaining function in cells utilizing the salvage pathway.

---

Physiological Consequence: Reduced Immune Expansion

By selectively limiting the proliferation and subsequent pool of activated, pro-inflammatory immune cells in the periphery, the mechanism reduces the expansion of the activated lymphocyte pool. This reduction in the proliferative expansion of lymphocytes is a key physiological consequence that alters immune cell proliferation rates.

Aubagio (teriflunomide) 14 mg is administered as a long-term, continuous oral therapy intended for managing chronic autoimmune conditions. The administration protocol focuses on ease of use and consistent daily intake.

---

Standard Administration Protocol

The medication is supplied as an oral film-coated tablet and is taken by mouth. The tablets must be swallowed whole with water and must not be crushed, dissolved, or chewed. The primary dose for adult use is 14 mg once daily, which forms the basis of the standard maintenance regimen. The once-daily frequency simplifies the treatment schedule, and the tablet can be taken at any time of day, with or without food.

---

Dosage and Population Specifics

While the adult dose is fixed at 14 mg, dosing for pediatric patients (age 10 years and older) is determined by body weight, requiring either 7 mg or 14 mg once daily. For all patients, treatment must be initiated and supervised by a physician experienced in managing the condition.

If a dose is missed, the patient should simply resume the schedule by taking the next dose at the regularly scheduled time; double dosing is strictly prohibited to compensate for the missed tablet. No dose adjustment is generally required for patients with mild to moderate renal or hepatic impairment not undergoing dialysis.

Aubagio 14mg: Recent Clinical Evidence

Clinical evidence supporting the use of Aubagio (teriflunomide) 14 mg for relapsing forms of Multiple Sclerosis (MS) is primarily drawn from key Phase 3 trials and their long-term extension studies, which focused on reducing the frequency of relapses and slowing disability progression.

---

Pivotal Phase 3 Trial Outcomes

The efficacy of the 14 mg dose was established in the TEMSO and TOWER studies, which were randomized, double-blind, placebo-controlled trials in patients with relapsing MS. These trials tracked patient outcomes over approximately two to three years.

Outcome Measure	Aubagio 14 mg vs. Placebo (TEMSO)	Aubagio 14 mg vs. Placebo (TOWER)
Annualized Relapse Rate (ARR)	Observed reduction in ARR	Observed reduction in ARR
Sustained Disability Progression	Observed reduced risk of progression	Observed reduced risk of progression
MRI Activity	Reduction in the number of active lesions	Reduction in the number of active lesions

In the TEMSO trial, patients receiving Aubagio 14 mg showed a reduction in the annualized relapse rate and a decreased risk of sustained accumulation of disability compared to those receiving placebo.

---

Long-Term Follow-up and Safety

Long-term extension studies have followed participants for up to nine years, providing sustained data on the 14 mg dose. These follow-up studies generally found that the observed benefits on relapse rate and disability progression were maintained over time.

The safety profile observed in the long-term extensions remained consistent with that of the core trials, with no new or unexpected safety concerns being identified. The most common adverse events reported in the clinical program included hair thinning, diarrhea, nausea, and elevations in liver enzyme levels.

Official Storage and Disposal Requirements

Storage & Disposal Entity	Regulatory Requirement
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).
Protection Requirements	Keep in a dry place and protect from excess heat. The medication must be kept from freezing.
Container Integrity	The tablets must be kept in the original container and the container must be tightly closed.
Child Safety	It is mandatory to keep this medication out of the sight and reach of children.
Disposal Instructions	Unused or outdated medicine should be disposed of according to local regulations after consulting a healthcare professional. Do not dispose of the tablets via household drains or wastewater.

---

The regulatory labeling defines strict environmental control for the tablets, mandating storage within a specific room temperature range and protection from freezing and moisture to maintain stability. Handling rules require the product to remain in its original, sealed container and emphasize mandatory child-safety storage. Disposal instructions direct patients to follow professional guidance and local environmental procedures for discarding unused product.